Creating a new treatment approach for aggressive breast cancer
Developing a novel combination immunotherapy for triple-negative breast cancer
This study is looking at new ways to treat triple-negative breast cancer by combining immune therapy with special drugs that target the cancer's surroundings, and it's for patients who want to know if they might benefit from this approach.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Hawaii at Manoa NIH-funded |
| Lab location | 1 site (Honolulu, United States) |
| Project ID | NIH-10930903 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The team aims to combine immunotherapy with specific inhibitors that target the tumor microenvironment, which is crucial for the cancer's growth and resistance to treatment. By understanding how certain pathways influence the immune response in TNBC, the researchers hope to identify new biomarkers that can predict which patients will benefit from this combination therapy. The study will involve laboratory experiments and may lead to clinical trials for patients who qualify.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded well to standard treatments.
Not a fit: Patients with non-triple-negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using combination therapies for cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Honolulu, United States
- University of Hawaii at Manoa — Honolulu, United States (Active)
Researchers
- Principal investigator: Ueno, Naoto T. — University of Hawaii at Manoa
- Study coordinator: Ueno, Naoto T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.